| Document |
Document Title |
|
WO/2003/088959A2 |
A method of treating, preventing, or inhibiting PD, in a subject in need of such treatment, inhibition or prevention. The method comprises treating the subject with one or more cyclooxygenase-2 selective inhibitor(s), ester(s), salt(s) o...
|
|
WO/2003/089418A1 |
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases and to pharmaceutical compositions containing these comp...
|
|
WO/2003/086287A2 |
Compounds useful for inducing apoptosis in proliferate cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer...
|
|
WO/2003/087077A1 |
A process for the preparation of N-debenzoylpaclitaxel (I) through esterification of 7-protected baccatin III with a carboxylic acid reactive derivative of general formula (II), and elimination of the ester-protecting groups in acid cond...
|
|
WO/2003/087062A2 |
The present invention describes novel compounds of formula (I) having antiinflammatory activity, process for their preparation and pharmaceutical composition containing them.
|
|
WO/2003/087068A1 |
The present invention is directed to a novel process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents that are useful in the synthesis of a variety of pharmaceuticals, in particular certain cysteine protease in...
|
|
WO/2003/087037A1 |
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...
|
|
WO/2003/084915A1 |
This invention relates to novel compounds according to the general formula : which are thyroid receptor ligands, preferably antagonists, partial antagonists or partial agonists and to methods for using such compounds in the treatment of ...
|
|
WO/2003/084919A2 |
The invention concerns novel methods for preparing combretastatins by Wittig condensation between nitromethoxy-benzaldehyde and a trimethoxybenzyl phosphonium salt or inversely a nitromethoxybenzyl phosphonium salt with trimethoxybenzyla...
|
|
WO/2003/084964A1 |
The present invention relates to derivatives of 1-oxa-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory a...
|
|
WO/2003/084927A1 |
Haloalkenes represented by the general formula (I) which are useful as pest controllers: (I) wherein X1 and X2 are each halogeno; Y is hydrogen or halogeno; n is 0 to 5; and Q is (1) a heterocyclic group selected from among thienyl, fury...
|
|
WO/2003/084535A1 |
Compounds of formula (I): X, E, and R' have any of the values defined in the specification, and their pharmaceutically acceptable salts, lower blood glucose levels and are useful for treating diseases in mammals such as Non-Inuslin Depen...
|
|
WO/2003/084534A1 |
A method of treating a diabetic foot infection in a mammal includes oral, parenteral, or intravenous administration of a pharmaceutical formulation containing an orally, parenterally, or intravenously-effective amount, respectively of an...
|
|
WO/2003/082280A1 |
Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5 and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds,...
|
|
WO/2003/082263A1 |
The present invention relates to certain substituted sulfamic acids, which exhibit inhibitory action against Human Cytoplasmic Protein Tyrosine Phosphatases (HC-PTPs, Low Molecular Weight Protein Tyrosine Phosphatases, Orthophosphoric Mo...
|
|
WO/2003/082864A2 |
The present invention relates to novel compounds of general formula (I), their analogs, their derivatives, their stereoisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts an...
|
|
WO/2003/082822A1 |
The invention relates to novel phenethylacrylamides of formula (I), in which the substituents R1, R2, R3 and R4 are defined as follows: R1 represents hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C8 cycloalkyl, C1-C4 haloalkoxy or C1-...
|
|
WO/2003/080545A2 |
Substituted phenylacetic acids, phenylethanols and related compounds are provided that are useful in treating or controlling a number of diseases associated with glucose metabolism, lipid metabolism and insulin secretion.
|
|
WO/2003/080042A1 |
A medicinal composition which contains a compound represented by the general formula (I): (I) wherein R1 is hydroxy, etc.; R2 is optionally substituted lower alkyl, etc.; R3 is hydrogen, etc.; R4 is optionally substituted allylene, etc.;...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/077828A2 |
The present invention relates to novel florfenicol compounds having the chemical structure (I) wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without lim...
|
|
WO/2003/078376A1 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough.
|
|
WO/2003/076420A1 |
The invention relates to compounds of formula (I), the pharmaceutically acceptable derivatives, salts, solvates, stereoisomers and mixtures thereof, where X, Y, Z, R1, R3, R4, R8, p, k, E, G, Z and Q have the meanings given in claim 1, w...
|
|
WO/2003/076934A1 |
Sandwich assay kits for detecting shigatoxins which comprise a combination of a monoclonal antibody reacting specifically with shigatoxin CTX3C produced by a hybridoma 3D11 (ACCESSION NUMBER FERM BP-8293) with another monoclonal antibody...
|
|
WO/2003/076396A1 |
A novel process for synthesizing a ß-aminoketone which comprises reacting an &agr ,ß-unsaturated ketone compound with a carbamate compound through conjugate addition, in which a salt or hydrated salt of a transition metal belonging to ...
|
|
WO/2003/076405A1 |
The present invention relates to monocyclic aroylpyridinones, processes for their preparation, and their use in medicaments, especially for the treatment of COPD: (formula I).
|
|
WO/2003/075923A1 |
A VDAC regulator which contains a compound represented by the formula (I): (I) (wherein R1 represents halogeno, an optionally substituted heterocyclic group, optionally substituted hydroxy, optionally substituted thiol, or optionally sub...
|
|
WO/2003/075857A2 |
Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.
|
|
WO/2003/076407A1 |
Various chalcone derivatives of the general formula (I) are described and the variables, A, B, m and R1 to R10 are as defined in the specification. These derivatives can be useful in the modulation of potassium channel activity in cells ...
|
|
WO/2003/075836A2 |
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
WO/2003/074483A1 |
8-Azaprostaglandin represented by the following general formula (I), pharmacologically acceptable salts thereof or cyclodextrin clathrates of the same: (I) wherein each symbol is as defined in the description. Because of strongly binding...
|
|
WO/2003/074504A2 |
A process for the preparation of a compound of formula (IV), wherein, one of Y and Z is N and the other is S or O; comprising the steps of; a) treating of a compound of formula (I) with an alkyl lithium reagent, magnesium (0), or magnesi...
|
|
WO/2003/074038A1 |
METHODS FOR TREATING DISEASES RELATED TO INTRAOCULAR PRESSUREABSTRACT OF THE DISCLOSUREThis invention relates to the use of compounds able to decrease potassium ion flow through intermediate conductance calcium activated potassium channe...
|
|
WO/2003/073979A2 |
The invention relates to azaspiro compounds and to their use as drugs, especially for treating chronic, chronic-inflammatory and/or neuropathic pain. Compounds that are especially suitable for producing analgetics are 1,3-diazaspiro[4.5]...
|
|
WO/2003/074502A1 |
The invention relates to a method for producing substituted 5-alkoxy-substituted oxazoles, in particular, for producing 4-methyl-5-alkoxy-substituted oxazoles, and to a method for producing pyridoxine derivatives. thermal cyclization cyc...
|
|
WO/2003/074495A1 |
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseas...
|
|
WO/2003/072102A1 |
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein:(a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alke...
|
|
WO/2003/072100A1 |
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: (Formula I); wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl...
|
|
WO/2003/072572A1 |
The present invention provides β3-adrenergic receptor agonists of structural Formula (I) as well as pharmaceutical formulations thereof and methods for treating β3-adrenergic receptor-mediated diseases, conditions, or disorders using s...
|
|
WO/2003/072554A1 |
Compounds represented by the general formula (I) or salts thereof which are useful in the prevention or treatment of diabetic neuropathy and so on: (I) wherein R1 is hydrogen, halogeno, an optionally substituted hydrocarbon group, an opt...
|
|
WO/2003/072535A2 |
This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2003/072532A1 |
A novel therapeutic agent for hyperlipemia which is an ester compound represented by the general formula (1'): (1') [wherein R1 and R2 each is hydrogen, optionally substituted aryl, etc.; X is -COO- or -CON(R10)-; R3 and R4 each is hydro...
|
|
WO/2003/072101A1 |
The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment ...
|
|
WO/2003/072553A1 |
Compounds of formula B-C-A-CO-NH-R1, wherein A is structure i, ii or iii: formulae (I), (II), (III). C is optionally substituted aryl or heteroaryl, and B is a specified cyclic moiety, or C and B together are a heterobicyclic moiety, are...
|
|
WO/2003/070277A1 |
It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having a cannabinoid receptor agonism shows an antipruritic effect.
|
|
WO/2003/069350A2 |
The present invention provides methods of identifying modulators of apoptosis. Additionally provided are methods of contacting a cell with a compound capable of decreasing the amount of cyto c necessary to form an active apoptosome, and ...
|
|
WO/2003/068759A1 |
Compounds of formula (I) wherein: R1-R6.X.Y are as defined in the description and salts and solvates thereof, are CCR-3 antagonists and are thus indicated to be useful in therapy.
|
|
WO/2003/068779A1 |
The invention relates to cyclic compounds of the general formula (I), in which the groups are defined as follows: X-Y-Z represent N=C-O, NH-C=N, N=C-NH and R1, R2, R3 represent H, C1-6 alkyl, and of the general formula (III), in which th...
|
|
WO/2003/068226A1 |
The present invention relates to compounds of formula (I): wherein one of R1 and R4 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; an...
|
|
WO/2003/068730A1 |
The invention relates to an improved method for producing 3-phenylamino-propane-1,2-diols. 3-Phenylamino-propane-1,2-diols are valuable intermediates that can be reacted further to 3-phenyloxazolidinone compounds.
|
